Chun Felix K-H, Karakiewicz Pierre I, Huland Hartwig, Graefen Markus
Department of Urology, University of Hamburg, Martinistrasse 52, 20246 Hamburg, Germany.
World J Urol. 2007 Apr;25(2):131-42. doi: 10.1007/s00345-007-0146-y. Epub 2007 Feb 27.
Nomograms have been developed to predict prostate cancer (PCa) related outcomes. We report what has been achieved and what can be expected in 2007 and in the future. We reviewed the literature to provide guidelines in terms of criteria, limitations and clinical value of nomograms in 2007. Further, we report a set of recent PCa nomograms, where certain criteria are listed which were used to develop each nomogram. Our findings suggest a demand for an update of nomograms as well as head-to-head comparisons to determine the best-suited model in select fields of PCa outcomes. In 2007 and the future, an increasing number of nomograms will address important endpoints such as PSA recurrence, local and distant metastases, or androgen-independent PCa-specific survival. Our results suggest that nomograms represent valid risk stratification models to achieve most accurate predictions. In 2007 and the future, more specific and refined nomograms will be available which address relevant clinical end points. Moreover, novel markers in PCa outcomes will be quantified using the nomogram approach.
已经开发出列线图来预测前列腺癌（PCa）相关结局。我们报告了2007年已经取得的成果以及未来的预期。我们回顾了文献，以提供2007年列线图在标准、局限性和临床价值方面的指导方针。此外，我们报告了一组近期的PCa列线图，并列出了用于开发每个列线图的某些标准。我们的研究结果表明，需要更新列线图，并进行直接比较以确定PCa结局特定领域中最合适的模型。在2007年及未来，越来越多的列线图将涉及重要终点，如PSA复发、局部和远处转移或去势抵抗性PCa特异性生存。我们的结果表明，列线图是实现最准确预测的有效风险分层模型。在2007年及未来，将有更具体和精细的列线图可用于解决相关临床终点问题。此外，将使用列线图方法对PCa结局中的新型标志物进行量化。
